Name: 疫情結束為何可能提振醫療股？ (Why the end of the pandemic may boost health care stocks)
Uploaded: 2021-01-30T21:40:47.000Z
Duration: 4 min 51 s

Our sector today is health care, and our guest is Randy Watts, the chief investment officer for O Neill Global Advisors.

我們今天的行業是醫療保健，我們的嘉賓是O Neill Global Advisors的首席投資官Randy Watts。

With global headlines currently dominated by news of the rollout of various coronavirus vaccines, you might be surprised that stocks in vaccine makers have had Apache year, as has the sector.

目前，全球頭條新聞都被各種冠狀病毒疫苗推出的新聞所佔據，你可能會驚訝於疫苗製造商的股票有阿帕奇年，該行業也是如此。

Shares in Pfizer, for example, of fared poorly on a trading at about the same level they were a year ago.

例如，輝瑞公司的股票在交易上表現不佳，大約在一年前的水準。

Drugmakers in general suffered as people stayed away from hospitals and doctors as the pandemic raged.

由於疫情肆虐，人們遠離醫院和醫生，藥商普遍受到影響。

But the S and P 500 Healthcare Index includes not only drugmakers, but health insurers and medical supply makers.

但S和P 500醫療保健指數不僅包括藥品製造商，還包括健康保險公司和醫療用品製造商。

Accounts Johnson and Johnson, United Health and Pfizer is the top three holdings.

賬戶強生、聯合健康和輝瑞是前三名持股。

Three indexes, up a modest 12% over the past year.

三個指數，過去一年小幅上漲12%。

So is this a sector investors should be looking at in 2021 with vaccine rollouts underway?

那麼在2021年，隨著疫苗的推廣，這是否是投資者應該關注的行業呢？

Let's find out with O Neill Global Advisors chief investment officer Randy Watts, Randi.

讓我們和奧尼爾全球顧問公司首席投資官蘭迪-沃茨、蘭迪一起了解一下。

Thanks for joining us, given the sector's fairly average performance over the last year, why is this something investors should be looking at well, first thanks for having me back.

謝謝你參加我們的節目，鑑於去年該板塊的表現相當一般，為什麼這是投資者應該關注的好，首先感謝你邀請我回來。

The reason we like health care and you hit on it a little bit at the opening comments is that we believe there's a lot of pent up demand.

我們之所以喜歡醫保，你在開篇評論的時候也說到了一點，就是我們相信有很多的積壓需求。

Ah, lot of elective surgeries and hospital visits and doctor visits were delayed because of co vid.

啊，很多擇期手術和住院、看病都因為co vid耽誤了。

And as we come out of this pandemic, we think those we're going to really pick up and lead to better than average revenue and earnings growth for the sector versus the overall market.

而當我們走出這場流行病時，我們認為這些我們將真正回升，並導致該行業的收入和盈利增長優於整體市場的平均水平。

You say, though, that there are multiple cross currents to be aware of in health care.

你說，不過，在保健方面要注意多個交叉電流。

Well, we do think you really want to focus on testing medical devices and select areas of Bio Pharma, and the area we would avoid in the US right now is actually managed care so that the Biden administration coming in, they're looking to reassert some elements of the Affordable Care Act, and that could impact the margins of managed care companies like a united health negatively.

好吧，我們確實認為你真的想專注於測試醫療設備和生物製藥的選定領域，我們現在在美國會避免的領域實際上是管理式醫療，所以拜登政府上臺後，他們希望重新確認平價醫療法案的一些內容，這可能會對管理式醫療公司的利潤產生負面影響，比如聯合健康。

So we really want to focus on devices and testing companies like Abbott Labs, who reported this morning and had great numbers they beat on revenues and earnings and raised their guidance for 2021 companies like Intuitive Surgical.

是以，我們真的想關注設備和測試公司，如雅培實驗室，他們今天早上報告，有很好的數據，他們在收入和盈利方面取得了勝利，並提高了他們對2021年公司的指導，如Intuitive Surgical。

We think elective surgeries were really going to spike in the second half of the year.

我們認為下半年擇期手術真的會激增。

And Neo Genomics, which is a company that does testing for both co vid and oncology, given Aled that, then how would you advise investors to approach healthcare?

而Neo Genomics是一家同時做co vid和腫瘤檢測的公司，既然Aled這樣說，那麼你會建議投資者如何對待醫療保健？

I would say it is a little bit of a stock picker's market right now.

我想說的是，現在是一個有點選股的市場。

Uh, the Onley sector in health care that's actually down over the last two months is managed care.

在過去的兩個月裡，醫療服務中的Onley部門實際上是下降的，就是管理式醫療。

So as I mentioned, we would avoid that we would try to be overexposed to devices and testing.

是以，正如我所提到的，我們會避免我們會盡量對設備和測試過度暴露。

If you look at health care, it's actually started to pick up recently, so it lagged last year.

如果你看保健品，其實最近開始回暖了，所以去年就滯後了。

This year it's actually going in today's trading up more than the S and P by about 50 basis points.

今年其實在今天的交易中，它的漲幅要比S和P高出50個基點左右。

So we do think this is a sign of things to come, and we do think relative performance is gonna be better as we move through 2021 overall, then his health care by hold or sell.

所以我們確實認為這是一個信號，我們確實認為相對的表現會更好，因為我們整體進入到2021年，然後他的醫療保健通過持有或出售。

We think investors should be focusing on growth stocks.

我們認為投資者應該關注成長股。

We think there's an awful lot of good news and a lot of the cyclical recovery place.

我們認為有一個非常多的好消息和很多的週期性復甦的地方。

So we wanna be with secular growers that have new technology that can really and invigorate their revenues.

是以，我們希望與世俗的種植者，有新的技術，可以真正和振興他們的收入。

And we think health care is one of the places you can find that thanks so much for that.

我們認為醫療保健是一個地方，你可以找到，非常感謝。

That was Randy Watts of O Neill Global Advisors.

那是奧尼爾全球顧問公司的蘭迪-瓦茨。

Before I go, then here are some of the top stories in the sector.

在我去之前，那麼這裡有一些部門的頂級故事。

President Biden will issue an executive order reopening the nation's online health insurance marketplace that had been shut down by former President Donald Trump.

美國總統拜登將發佈行政命令，重新開放曾被前總統特朗普關閉的全國在線醫療保險市場。

Americans who can't get health insurance through their employer will be able to sign up from February 15th andan International fight over vaccine supplies intensified on Thursday.

不能通過僱主獲得健康保險的美國人將能夠從2月15日開始註冊，週四，國際上關於疫苗供應的鬥爭加劇了。

The European Union says it will tighten oversight of exports after around with AstraZeneca on Britain demanded that it received the shots it paid for the US far behind Britain and the United States in rolling out vaccines.

歐盟表示，將加強對出口的監督後，周圍與阿斯利康對英國要求收到它支付的鏡頭美國遠遠落後於英國和美國推出疫苗。

It's scrambling to get supplies as AstraZeneca and other big vaccine makers slow deliveries due to production problems on Germany's vaccine committee, says that AstraZeneca's Cove in 19 vaccine should only be given to people aged 18 to 64.

由於德國疫苗委員會的生產問題，阿斯利康和其他大型疫苗製造商放慢了交付速度，它正在爭奪供應，稱阿斯利康的Cove in 19疫苗只應給予18至64歲的人。

The recommendation comes only one day ahead of a decision by European regulators On the jab, the committee said there's insufficient data available to assess efficacy for those aged 65 over, and that's your roundup of the health care sector.

該建議僅在歐洲監管機構作出決定的前一天，該委員會表示，對於那些65歲以上的人來說，沒有足夠的數據可用來評估療效，這是你對醫療保健部門的總結。

我是埃琳娜-卡薩斯，這裡是路透社。

字幕列表影片播放

疫情結束為何可能提振醫療股？ (Why the end of the pandemic may boost health care stocks)

pandemic

average

impact

intuitive